摘要
司来吉兰是一种选择性不可逆的单胺氧化酶B抑制剂,目前不仅作为帕金森病(PD)早期的一线治疗药物,而且作为PD晚期的辅助治疗药物被广泛运用。司来吉兰治疗PD具有独特的优势,能够改善早期PD的症状和体征,延缓其进程,保护神经元;对晚期PD辅助左旋多巴治疗也有较好的疗效。但其也有不良反应。本文介绍司来吉兰在临床应用的进展。
Selegiline is a selective irreversible monoamine oxidase type B（MAO-B） inhibitor, widely used in the treatment of Parkinson＇s disease（PD）. Selegiline is not only as the first-line treatment in the early PD, but also as adjuvant treatment in the advanced PD. The method of selegiline in treatment of PD has its unique advantages on improving signs and symptoms of PD, slowing the process of PD, and protecting neurons. In addition, selegiline has a good effect in supporting levodopa for advanced PD. However, there are some side effects. This paper will give a review on its clinical application.
出处
《中国临床神经科学》
2008年第4期407-410,共4页
Chinese Journal of Clinical Neurosciences
关键词
司来吉兰
帕金森病
治疗
selegUine
Parkinson＇s disease
treatment
